>>SOUTH SAN FRANCISCO, Calif. (AP) -- Biopharmaceutical company CoTherix Inc. on Thursday forecast sales of its inhalable high blood pressure medication slightly above Wall Street expectations for the fourth-quarter and year.
The company forecast sales of its Ventavis inhaled prostacyclin therapy of about $11 million, up 30 percent from the third quarter. Ventavis treats pulmonary arterial hypertension, or high blood pressure in the artery that connects the heart to the lungs.
CoTherix estimates sales of Ventavis, which was launched in March, of about $23.9 million for 2005.
Looking forward, the company estimates 2006 sales of between $65 million and $70 million. CoTherix plans to provide additional guidance when it reports fourth-quarter earnings on March 6.
Analysts surveyed by Thomson Financial expected a quarterly loss per share of 29 cents on revenue of $10.7 million, a loss of $1.14 on revenue of $23.6 million in 2005. For 2006, Wall Street expects a loss of 46 cents on revenue of $67.1 million.<<
Back in the $10 range, maybe worth a look? Still no options for hedging,though . . .
Cheers, Tuck |
